[Retracted] Chemotherapy with a TP Regimen in Combination with Stereotactic Radiotherapy Could Significantly Optimize the Clinical Efficacy of NSCLC Treatment

Table 5

Comparison of progression-free survival and total survival between the two groups.

Group	Number of cases	Progression-free survival (months)	Total survival (months)
Observation group	40	10.28 ± 2.01	12.36 ± 2.52
Control group	40	8.17 ± 1.58	10.24 ± 2.11
t		5.22	4.079
		<0.001	<0.001